• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PeerJ . SARS-CoV-2-specific humoral and cellular immunity assessment in Peruvian vaccinated population: a cross-sectional study

tetano

Editor, Senior Moderator
PeerJ


. 2025 Jul 15:13:e19651.
doi: 10.7717/peerj.19651. eCollection 2025. SARS-CoV-2-specific humoral and cellular immunity assessment in Peruvian vaccinated population: a cross-sectional study

Marlon Yuri Garcia-Paitan[SUP] 1 2 3 [/SUP], Salyoc Tapia-Rojas[SUP] 1 2 [/SUP], Hector Santiago Alvarez Vega[SUP] 1 2 [/SUP], Javier Enciso-Benavides[SUP] 4 [/SUP], Maria J Pons[SUP] 4 [/SUP], Ana Mayanga-Herrera[SUP] 1 2 [/SUP]



Affiliations
Abstract

Background: Evaluating both humoral and cellular immunity is essential for optimizing vaccination strategies and preventing post-pandemic SARS-CoV-2 outbreaks. This cross-sectional study assessed cellular immunity by measuring CXCL10 mRNA expression and humoral immunity through SARS-CoV-2-specific IgG antibodies.
Method: Whole blood samples were collected from 40 Peruvian volunteers. CXCL10 expression was evaluated in blood samples stimulated with Spike protein peptides from the Wuhan strain and Omicron BA.5 variant using RT-qPCR. Anti-spike IgG levels were measured with a semi-quantitative ELISA.
Results: The median age was 31 years, with 62.5% females. A heterologous vaccination scheme was reported by 73%, but only 25% received their last dose within the past 6 months, and 55% completed three doses. The BNT162b2 vaccine was included in 88% of vaccination schemes, serving as the first and second dose in 48% of cases. All participants had detectable anti-spike IgG antibodies; 90% exhibited cellular responses to Wuhan peptides and 97.5% to Omicron peptides. CXCL10 mRNA expression (2[SUP]-ΔΔCT[/SUP]) was significantly higher for Omicron (median: 565.97; IQR: 565,148.34) compared to Wuhan (median: 18.55; IQR: 62,898.67). Higher anti-spike IgG levels correlated with age and the number of vaccine doses. Males had significantly higher CXCL10 and anti-spike IgG levels (p < 0.05). Antibody levels were greater in those recently boosted or vaccinated with mRNA-1273 (p = 0.001, p = 0.002).
Conclusion: Most participants exhibited robust immunity, characterized by elevated levels of CXCL10 and anti-SARS-CoV-2 IgG antibodies. These findings highlight the importance of boosters in enhancing immunity and the need for diverse techniques for measuring immunity.

Keywords: CXCL10 mRNA; Cellular immunity; Humoral immunity; RT-qPCR; SARS-CoV-2; Vaccine.

 
Back
Top Bottom